Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
12,705
Total Claims
$1.3M
Drug Cost
1,247
Beneficiaries
$1,052
Cost/Patient
Risk Score Breakdown 21/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-19%
Opioid rate vs peers
1.8% vs 2.2% avg
-25%
Cost per patient vs peers
$1,052 vs $1,411 avg
+4%
Brand preference vs peers
11.1% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
1.8%
Opioid Rate
231
Opioid Claims
$10K
Opioid Cost
7.8%
Long-Acting Rate
Brand vs Generic
Brand: 1,391 claims · $1.0M
Generic: 11,175 claims · $258K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 88 | $121K |
| Fluticasone/Umeclidin/Vilanter | 56 | $90K |
| Mirabegron | 74 | $86K |
| Sitagliptin Phosphate | 61 | $75K |
| Semaglutide | 42 | $74K |
| Dapagliflozin Propanediol | 40 | $54K |
| Empagliflozin | 26 | $39K |
| Insulin Glargine,hum.Rec.Anlog | 34 | $37K |
| Dulaglutide | 27 | $34K |
| Insulin Degludec | 30 | $32K |
| Linaclotide | 37 | $31K |
| Denosumab | 18 | $30K |
| Rivaroxaban | 17 | $21K |
| Evolocumab | 14 | $20K |
| Sitagliptin Phos/Metformin Hcl | 12 | $16K |
Prescribing Profile
Patient Profile
75
Avg Age
59%
Female
1.45
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About